17.4 C
London
Thursday, September 21, 2023
HomeLatestEuropean Commission authorizes GSK's HIV prevention drug

European Commission authorizes GSK’s HIV prevention drug

Date:

Related stories

Missing F-35 jet was ‘almost going inverted’ before crash, witness says

The missing F-35 military jet presumed to have crashed...

King’s Hawaiian ‘Sunday Slider’ recipes are perfect for game day

HAWAIIAN HAM AND SWISS SLIDER PREP: 10 min. COOK: 20...

Kenya to lead multinational force in Haiti to combat gangs

Kenya’s president committed his country to leading a multinational...

Singapore police investigating money laundering scheme uncover more gold bars, luxury watches

Singapore police uncovered more luxury watches, gold bars and...
spot_imgspot_img

The European Commission has authorized GSK’s HIV-focused unit ViiV Healthcare’s cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.

EUROPEAN COMMISSION CHIEF URSULA VON DER LEYEN ASSURES AID TO FLOOD-STRICKEN SLOVENIA DURING VISIT

Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 77.16 pounds, according to the company.

Sold under brand name Apretude, it is currently approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img

LEAVE A REPLY

Please enter your comment!
Please enter your name here